Epithelial neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A benign or malignant neoplasm that arises from and is composed of epithelial cells. This category include adenomas, papillomas, and carcinomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Epithelial neoplasm
- Therapeutic area
- Oncology
- epithelial neoplasm
- epithelial neoplasm
- epithelioma
- All therapeutic areas
- Oncology
- Severity
- Unknown
- MONDO ID
- MONDO:0005626
- Parent condition
- MONDO:0005070
Related records
Broader conditions (6)
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (1,318)
- Acantholytic acanthoma
- Acantholytic squamous cell skin carcinoma
- Acantholytic variant squamous cell breast carcinoma
- Acanthoma
- Acinar cell carcinoma
- Acinar lung adenocarcinoma
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Acinic cell breast carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- ACTH-producing pituitary gland adenoma
- ACTH-producing pituitary gland carcinoma
- Adamantinoid basal cell epithelioma
- Adamantinoma
- Adamantinous craniopharyngioma
- Adenoacanthoma
- Adenocarcinoma
- Adenocarcinoma in situ
- Adenocarcinoma of gallbladder and extrahepatic biliary tract
Trials (10)
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
- First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
- First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
- Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
- Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
- Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
- Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
- Using Tumor Models to Determine Treatments